Core Viewpoint - PG&E Corporation (PCG) is set to report its second-quarter 2025 results on July 31, with expectations of revenue and earnings growth despite a previous earnings surprise of -5.71% in the last quarter [1][9]. Factors Influencing Q2 Results - Warmer-than-normal temperatures in PCG's service territories likely increased electricity demand for cooling, positively impacting revenues [2]. - Strong rate-based growth and favorable outcomes from previously approved general rate case filings are expected to contribute to revenue performance [2]. - Efforts to reduce non-fuel operations and maintenance (O&M) expenses may enhance earnings for the quarter [3]. Q2 Expectations - The Zacks Consensus Estimate for sales is $6.37 billion, reflecting a year-over-year growth of 6.4% [4]. - The consensus estimate for earnings is 33 cents per share, indicating a year-over-year increase of 6.5% [4]. Earnings Prediction Insights - The current Earnings ESP for PCG is 0.00%, making it challenging to predict an earnings surprise despite anticipated sales growth [5][9]. - PCG holds a Zacks Rank of 3, suggesting a neutral outlook [6]. Industry Comparisons - American Electric Power (AEP) is expected to report on July 30, with an Earnings ESP of +10.63% and a Zacks Rank of 3 [7]. - IDACORP Inc. (IDA) is also reporting on July 31, with an Earnings ESP of +4.55% and a Zacks Rank of 3 [10]. - Xcel Energy Inc. (XEL) is scheduled for July 31, with an Earnings ESP of +1.76% and a Zacks Rank of 3 [11].

Core Insights - Ponce Financial (PDLB) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, and showing an increase from $0.14 per share a year ago, resulting in an earnings surprise of +47.06% [1] - The company achieved revenues of $26.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.28% and up from $20.16 million year-over-year [2] - Ponce Financial has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise of +177.78% in the previous quarter indicates strong performance relative to expectations [1] - The current consensus EPS estimate for the upcoming quarter is $0.19, with projected revenues of $26.5 million, while the estimate for the current fiscal year is $0.79 on revenues of $103.5 million [7] Stock Performance and Outlook - Ponce Financial shares have increased approximately 5.5% year-to-date, compared to an 8.2% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Context - The Financial - Miscellaneous Services industry, to which Ponce Financial belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and earnings estimate revisions, which could impact Ponce Financial's stock performance [5]

Core Viewpoint - Investors are expected to focus on Altimmune's progress with its lead pipeline candidate, pemvidutide, during the second-quarter 2025 results announcement, as the company currently lacks a marketed drug and is projected to report a loss of 32 cents per share [1][10]. Group 1: Pipeline Candidate and Clinical Trials - Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist being developed for obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD), and alcohol use disorder (AUD) [2]. - The phase IIb IMPACT study showed that at 24 weeks, 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg achieved MASH resolution without worsening fibrosis, compared to 19.1% with placebo [3]. - Fibrosis improvement without worsening MASH was observed in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo, although these differences were not statistically significant [4]. Group 2: Weight Loss and Safety Profile - Participants receiving pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks, indicating a favorable weight loss profile [5]. - Treatment with pemvidutide was generally safe and well-tolerated, which is a positive aspect for its future development [5]. Group 3: Market Performance and Future Expectations - Year to date, Altimmune's shares have declined by 43%, contrasting with a 7.2% increase in the industry [5]. - The company has initiated two separate phase II studies for pemvidutide targeting AUD and ALD, with further updates expected during the upcoming earnings call [6][7]. - Operating expenses are anticipated to have decreased in the upcoming quarter due to the timing of clinical study costs [7]. Group 4: Earnings Surprise History - Altimmune has a mixed earnings surprise history, having beaten estimates in three of the last four quarters, with an average surprise of 9.21% [8]. - In the last reported quarter, the company posted an earnings surprise of 25.71% [8].

Core Insights - Newmont Corporation reported a revenue of $5.32 billion for the quarter ended June 2025, marking a 20.8% increase year-over-year and a surprise of +16.03% over the Zacks Consensus Estimate of $4.58 billion [1] - The earnings per share (EPS) for the quarter was $1.43, significantly higher than the $0.72 reported in the same quarter last year, resulting in an EPS surprise of +37.5% compared to the consensus estimate of $1.04 [1] Financial Performance Metrics - Newmont's stock has returned +5.8% over the past month, slightly outperforming the Zacks S&P 500 composite's +5.7% change, and currently holds a Zacks Rank 2 (Buy) [3] - Attributable Gold Production from Yanacocha was 131.00 Koz, exceeding the two-analyst average estimate of 112.26 Koz [4] - Consolidated silver production was reported at 8,000.00 Koz, surpassing the average estimate of 7,064.04 Koz [4] Geographic Revenue Breakdown - Revenue from Nevada Gold Mines was $783 million, exceeding the estimated $747.19 million, representing a +39.1% change year-over-year [4] - Peñasquito generated $815 million in revenue, significantly higher than the estimated $699.12 million, reflecting a +125.8% year-over-year increase [4] - Merian's revenue was reported at $223 million, compared to the average estimate of $153.38 million, indicating a +114.4% change year-over-year [4] - Cerro Negro's revenue reached $112 million, surpassing the estimated $92.4 million, with a +12% change year-over-year [4] - Yanacocha's revenue was $446 million, exceeding the average estimate of $244.48 million, representing a remarkable +237.9% change year-over-year [4] - Lihir's revenue was $517 million, compared to the average estimate of $478.17 million [4] - Tanami's revenue was $297 million, exceeding the estimated $262.73 million, with a +21.7% change year-over-year [4] - Ahafo generated $657 million in revenue, surpassing the average estimate of $528.69 million, reflecting a +149.8% year-over-year change [4]

Core Insights - Alexander & Baldwin Holdings, Inc. reported $51.7 million in revenue for the quarter ended June 2025, reflecting a year-over-year increase of 1.3% and an EPS of $0.48 compared to $0.16 a year ago [1] - The reported revenue slightly exceeded the Zacks Consensus Estimate of $51.6 million, resulting in a surprise of +0.2%, while the EPS surprise was +23.08% against a consensus estimate of $0.39 [1] Financial Performance - Operating Revenue from Commercial Real Estate was $50.73 million, which was below the estimated $51.12 million, but showed a year-over-year increase of +3.1% [4] - Operating Revenue from Land Operations was reported at $0.97 million, significantly lower than the estimated $6.85 million, indicating a year-over-year decline of -47.2% [4] - Diluted earnings per share were reported at $0.35, surpassing the average estimate of $0.22 based on three analysts [4] Market Performance - Shares of Alexander & Baldwin Holdings have returned +1.9% over the past month, in contrast to the Zacks S&P 500 composite's +5.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Wall Street anticipates a year-over-year decline in Beazer Homes' earnings due to lower revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Earnings Expectations - Beazer Homes is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year decrease of 52.3% [3]. - Projected revenues for the quarter are $554.33 million, down 6.9% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.36% higher in the last 30 days, indicating a slight positive reassessment by analysts [4]. - The Most Accurate Estimate for Beazer is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.76%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank of 1, 2, or 3 [10]. - Beazer currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Beazer exceeded the expected earnings of $0.26 per share, achieving $0.42, which resulted in a surprise of +61.54% [13]. - Over the past four quarters, Beazer has beaten consensus EPS estimates three times [14]. Conclusion - While Beazer does not appear to be a compelling earnings-beat candidate, investors should consider other factors before making investment decisions [17].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Intercontinental Exchange (ICE) due to higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - ICE is expected to report quarterly earnings of $1.76 per share, reflecting a +15.8% change year-over-year, and revenues of $2.52 billion, which is an 8.8% increase from the previous year [3]. - The consensus EPS estimate has been revised 1.14% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +0.51% for ICE, suggesting analysts are optimistic about the company's earnings prospects [12]. - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - ICE has beaten consensus EPS estimates in three out of the last four quarters, with a recent surprise of +1.18% when it reported earnings of $1.72 per share against an expectation of $1.70 [13][14]. Conclusion - ICE is viewed as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond just earnings results [15][17].

Company Overview - Howmet (HWM) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.87, reflecting a +29.9% change, and revenues of $1.99 billion, up 5.8% from the previous year [3][11] Earnings Expectations - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The upcoming earnings report is anticipated to be released on July 31, and the stock may react positively if actual results exceed expectations [2][11] Earnings Surprise Prediction - Howmet's Earnings ESP is -0.14%, suggesting a bearish outlook from analysts, which complicates the prediction of an earnings beat [11] - The company holds a Zacks Rank of 3, indicating a hold position, which further adds uncertainty to the earnings prediction [11] Historical Performance - In the last reported quarter, Howmet exceeded EPS expectations by +11.69%, with actual earnings of $0.86 compared to an expected $0.77 [12] - Over the past four quarters, Howmet has successfully beaten consensus EPS estimates each time [13] Industry Context - In the Zacks Aerospace - Defense industry, Boeing (BA) is expected to report a loss of $1.47 per share, with a year-over-year change of +49.3%, and revenues projected at $21.86 billion, up 29.6% [17][18] - Boeing's consensus EPS estimate has been revised 1.7% lower, and it also holds a Zacks Rank of 3, indicating similar uncertainty regarding its earnings performance [18][19]

Core Viewpoint - CVS Health is expected to report a year-over-year decline in earnings despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - CVS Health is projected to post quarterly earnings of $1.47 per share, reflecting a year-over-year decrease of 19.7% [3]. - Revenues are anticipated to reach $93.72 billion, which is a 2.7% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.55% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Most Accurate Estimate for CVS Health is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.06% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - CVS Health has a Zacks Rank of 2, indicating a strong potential for beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, CVS Health exceeded the expected earnings of $1.71 per share by delivering $2.25, resulting in a surprise of +31.58% [13]. - Over the past four quarters, CVS Health has consistently beaten consensus EPS estimates [14]. Industry Context - In the Zacks Medical Services industry, Teladoc is expected to report a loss of $0.27 per share, with a year-over-year change of +3.6% [18]. - Teladoc's revenue is projected to be $620.91 million, down 3.4% from the previous year [18]. - The consensus EPS estimate for Teladoc has been revised down by 3.9% in the last 30 days, resulting in an Earnings ESP of -13.8% [19].

Core Viewpoint - IdaCorp (IDA) is anticipated to report flat earnings of $1.71 per share for the quarter ended June 2025, with revenues expected to reach $453.36 million, reflecting a 0.5% increase from the previous year [3][12]. Earnings Expectations - The upcoming earnings report is scheduled for July 31, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2][12]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Most Accurate Estimate for IdaCorp is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.34%, suggesting a likelihood of beating the consensus EPS estimate [12]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, IdaCorp had an earnings surprise of +6.80%, reporting $1.10 per share against an expectation of $1.03 [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates three times [14]. Investment Considerations - While an earnings beat can influence stock movement, other factors may also play a significant role in determining stock performance post-earnings release [15]. - Investors are encouraged to consider both Earnings ESP and Zacks Rank when evaluating potential investment opportunities ahead of earnings announcements [16].